ZURICH (Reuters) - Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.
“Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care,” Roche’s Chief Medical Officer Sandra Horning said in a statement.
Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin
Our Standards: The Thomson Reuters Trust Principles.